Core Viewpoint - Incyte Corporation (英矽智能) successfully listed on the Hong Kong Stock Exchange, closing at HKD 29.98, representing a 24.66% increase from its offering price of HKD 24.05 [1][5]. Group 1: Offering Details - The total number of shares offered globally was 94,690,500, with 9,469,500 shares available for public offering in Hong Kong and 85,221,000 shares for international offering [2]. - The total proceeds from the offering amounted to HKD 2,277.3 million, with net proceeds after estimated listing expenses of HKD 251.5 million being HKD 2,025.8 million [5][6]. Group 2: Use of Proceeds - Approximately 48.0% of the net proceeds will be allocated to further clinical research and development of key pipeline candidates [7]. - About 15.0% will be used for the development of new generative AI models and related validation research [7]. - Approximately 12.0% will be directed towards the further development and expansion of automated laboratories [7]. - Around 20.0% will fund early drug discovery and development, including preclinical and clinical stages of other pipeline candidates [7]. - The remaining 5.0% will be utilized for working capital and other general corporate purposes [7]. Group 3: Financial Performance - Incyte's revenues for the years 2022, 2023, 2024, and the first half of 2025 were USD 30.1 million, USD 51.2 million, USD 85.8 million, and USD 27.5 million, respectively [9]. - The company reported losses of USD 221.8 million in 2022, USD 211.6 million in 2023, USD 17.1 million in 2024, and USD 19.2 million in the first half of 2025, totaling USD 469.8 million in losses over the specified periods [9][10].
英矽智能港股募22.8亿港元首日涨24.7% 近三年半均亏